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Abstract
Metastasis is the leading cause of cancer-related death. This multistage process involves contribution from both tumour cells
and the tumour stroma to release metastatic cells into the circulation. Circulating tumour cells (CTCs) survive circulatory
cytotoxicity, extravasate and colonise secondary sites effecting metastatic outcome. Reprogramming the transcriptomic
landscape is a metastatic hallmark, but detecting underlying master regulators that drive pathological gene expression is a
key challenge, especially in childhood cancer. Here we used whole tumour plus single-cell RNA-sequencing in primary bone
cancer and CTCs to perform weighted gene co-expression network analysis to systematically detect coordinated changes in
metastatic transcript expression. This approach with comparisons applied to data collected from cell line models, clinical
samples and xenograft mouse models revealed mitogen-activated protein kinase 7/matrix metallopeptidase 9 (MAPK7/
MMP9) signalling as a driver for primary bone cancer metastasis. RNA interference knockdown of MAPK7 reduces
proliferation, colony formation, migration, tumour growth, macrophage residency/polarisation and lung metastasis. Parallel
to these observations were reduction of activated interleukins IL1B, IL6, IL8 plus mesenchymal markers VIM and VEGF in
response to MAPK7 loss. Our results implicate a newly discovered, multidimensional MAPK7/MMP9 signalling hub in
primary bone cancer metastasis that is clinically actionable.
Introduction
Primary bone cancer (PBC) is the third most common solid
childhood cancer with 52,000 new cases per year world-
wide [1]. PBC arises at the ends of long bones, usually on
either side of the knee/pelvis. PBC includes several
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molecular subtypes, of which osteosarcoma is the most
common. Osteosarcomas can occur in adults, but these are
usually secondary to radiation exposure or Paget’s disease
of bone [2, 3]. Major driver mutations for osteosarcoma
include tumour protein p53 (TP53) and RB transcriptional
corepressor 1 (RB1) structural variants that trigger chro-
mothripsis [4–7]. Around 25% of patients present with
detectable metastasis (85% with lung metastases, 15% with
skeletal metastases). Five-year survival with metastatic/
relapsed osteosarcoma is 15% [1, 8]. Survival rates have not
changed for more than four decades. A better understanding
of the molecular and cellular mechanisms that underpin
spread is urgent.
Metastasis is the leading cause of cancer-related death.
This multistage and complex process requires metastatic
cells to shed into the local vasculature, survive circulation,
extravasate at distant sites and proliferate. Metastasis
involves contribution from both tumour cells and tumour
stroma. The early stages of metastasis are relatively effi-
cient. Post-extravasation stages, that is, colonisation, are
critical in determining metastatic outcome [9]. It is largely
accepted that cancer arises from linear Darwinian evolution
involving competing subclones within a single tumour that
eventually culminates in lethal clones with metastatic cap-
ability. Evidence suggests that metastatic dissemination
may occur early where cells from incipient, low-density
lesions display more stemness and metastatic tendency than
cells from proliferative, high-density tumours [5, 9]. Ana-
lysis of secondary lesions to elucidate molecular properties
of spread is hampered by the extreme difficulty in obtaining
samples of metastatic disease because of a lack of surgical
intervention at that clinical stage. Circulating tumour cells
(CTCs) provide an alternative less invasive approach where
samples may be accessed throughout the disease course plus
reveal mechanisms of spread with the potential to identify
novel therapeutic strategies. CTC-based studies in breast,
prostate, and lung cancer show evidence of high WNT
signalling plus high haemoglobin subunit beta (HBB) to
support circulatory survival [10]. CTC clustering causes
demethylation of POU class 5 homeobox 1 (POU5F1),
SRY box 2 (SOX2), nanog homeobox (NANOG) and SIN3
transcription regulator family member A (SIN3A), all genes
paralleling stemness [11]. It still remains unclear how CTCs
are released from tumours. Studies suggest that interaction
between tumour cells and immune cells in the tumour
microenvironment influences metastatic progression
[12, 13]. Immunotherapies that target tumour stroma inter-
actions instead of tumours directly have shown efficacy in
several cancers shedding light on the possible treatment of
PBC [14].
Reprogramming the transcriptomic landscape in tumour
cells and in the tumour stroma is a metastatic hallmark, but
detecting underlying master regulators that drive
pathological gene expression is a key challenge, especially
in childhood cancer. Here we used an integrated analytical
approach that combines whole tumour plus single CTC
RNA-sequencing of patient samples (Supplementary File 1)
to search for PBC metastasis master regulators. A co-
expression network was built on all genes using a cut-off
mean (transcripts per millions (TPM) >5). We searched for
gene modules that were enriched for differentially expressed
(DE) genes. Modules enriched for DE genes were used to
reveal metastasis-associated genes. The functions of
metastasis-associated genes were enriched to determine the
importance of these genes in PBC spread. Using these clin-
ical datasets as a guide, we generated a xenograft mouse
model to mechanistically reveal a novel tumour cell–immune
cell interaction that drives PBC metastasis to the lungs.
Results
Recurrent HH, FGFR and IGF in whole tumours
An observation of immediate therapeutic significance was
the increased expression of hedgehog (HH), RUNX family
transcription factor 2 (RUNX2), fibroblast growth factor
receptor (FGFR) and insulin-like growth factor (IGF) in
whole tumours when compared to controls (Fig. 1a, b).
These data are consistent with our own and others’ obser-
vations, including the recent report of IGF1 amplification in
14% of osteosarcomas [1, 15, 16], although IGF1 plays less
of a role for driving primary tumour to metastatic tumour
gene expression (Fig. 1c). Given the poor osteosarcoma
prognosis and lack of treatment progress, our findings
provide a reason for exploring the efficacy of targeting these
pathways as first-line treatment. Sonidegib to target HH,
Lenvatinib to target FGFR and Cixutumumab, Dalotuzu-
mab and Robatumumab to target IGF have shown pro-
mising antineoplastic activity in other cancers [17–19].
Induction therapy activates folate receptor beta
Induction therapy for osteosarcoma in the United Kingdom
comprises high-dose methotrexate, doxorubicin and cis-
platin (MAP). We showed that the transcript for the cellular
receptor for folic acid uptake, folate receptor beta (FOLR2),
is upregulated in osteosarcoma exposed to MAP (Fig. 1a,
b). These data infer a biological mechanism for chemore-
sistance as methotrexate will be less obstructive to neo-
plastic folic acid metabolism.
Alternative splicing in several transcripts
Alternative splicing events are categorised as skipped exon,
retained intron, alternative 5′ splice site, alternative 3′ splice
D. Green et al.
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Fig. 1 Heat map-based hierarchical cluster analysis of DE genes
(x-axis) across tissue type (y-axis). Z-score refers to high (red) and
low (blue) gene expression using normalised values when compared to
the mean of total sequencing reads. Pie charts below each heat map
visually represent altered genes/pathways. a Control bone versus pri-
mary tumour. b Control bone versus metastatic lesion. c Primary
tumour versus metastatic lesion. There were few differences in gene
expression between MAP-treated and non-MAP-treated patients.
Patients are presented as one cohort, which will also include endo-
genous genetic heterogeneity. Each transcript presented has passed
log2 fold change ≥2, p ≤0.05 and FDR ≤ 5% parameters.
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site and mutually exclusive exon. We report events in
several transcripts not previously implicated in osteo-
sarcoma (Supplementary Fig. 1). These transcripts include
2-oxoglutarate and iron-dependent oxygenase domain con-
taining 2 (OGFOD2), autophagy-related 4D cysteine pep-
tidase (ATG4D), tropomyosin 1 (TPM1), transmembrane
protein 218 (TMEM218), copine 1 (CPNE1) and WW
domain binding protein 1 (WBP1) (Supplementary Fig. 1).
These DE transcripts harbour four of five alternative spli-
cing events.
Single osteosarcoma CTCs
We achieved <500,000 mapped reads in single CTCs (Fig.
2a) and >30 million mapped reads in whole tumours, so it
was inappropriate to directly compare DE genes. We per-
formed numerical expression plus enrichment analysis to
intersect the dataset between primary and secondary
tumours (Supplementary File 2). There was abundance of
mitochondrial gene expression, including mitochondrially
encoded cytochrome c oxidase I, II and III (MT-CO1, 2, 3),
mitochondrially encoded NADH:ubiquinone oxidor-
eductase core subunits 1–4 (MT-ND1, 2, 3, 4) and mito-
chondrially encoded cytochrome b (MT-CYB) (Fig. 2b).
These transcripts are central to oxidative phosphorylation.
Consistent with other cancer types, there was abundance of
stress tolerance with expression of HBB and ubiquitin C
(UBC) (Fig. 2b). There were markers of stemness and
embryonic activation with expression of MET proto-onco-
gene, receptor tyrosine kinase (MET), fibroblast growth
factor 10 (FGF10), fibronectin 1 (FN1), transforming
growth factor beta 2 (TGFB2) and RUNX2 (Fig. 2b). There
was also an abundance of collagen-associated transcripts
(Fig. 2b). There was a low expression of mitochondrial
fission factor (MFF), transcripts for RNA processing,
including cyclin C (CCNC), sirtuin 7 (SIRT7), enhancer of
mRNA decapping 4 (EDC4) and dicer 1, ribonuclease III
(DICER1) (Fig. 2c). There was a low transcript number for
BRCA1-associated protein 1 (BAP1), which when highly
expressed suppresses metastasis (Fig. 2c) [20]. STRING
analysis showed a functional interaction between all tran-
scripts (Fig. 2d).
CYP4B1, FGFR4 and ETS transcription factors in
secondary tumours
Principal component analysis (PCA) showed grouping
between controls, primary tumours and metastases (Fig. 3a).
PCA demonstrates the transcriptional trajectory of meta-
static progression (Fig. 3a). Gene expression differences
included upregulated drug metabolism via cytochrome
P450 family 4 subfamily B member 1 (CYP4B1) (Fig. 1c).
Metastases showed cell adhesive properties via cadherin 1
(CDH1), claudin 18 (CLDN18) and epithelial cell adhesion
molecule (EPCAM) (Fig. 1c). There was abundance of
fibroblast growth factor receptor 4 (FGFR4), Erb-b2
receptor tyrosine kinase 3 (ERBB3) and E74-like ETS
transcription factor 3 (ELF3) expression (Fig. 1c).
WGCNA discriminates metastasis
Patterns of genes in tissue types can be identified by
weighted gene co-expression network analysis (WGCNA).
WGCNA is an unsupervised and unbiased analysis that
identifies genes with similar expression patterns across
samples and assigns correlated genes to distinct co-
expression modules [21]. In contrast to standard analysis
for network analysis such as cytoscape based approaches,
WGCNA seeks to identify higher-order relationships among
genes by transforming gene expression profiles into func-
tional co-expressed gene modules. Within groups of highly
co-expressed genes or ‘modules’ that comprise core func-
tional units of transcriptional networks, WGCNA identifies
central genes connecting the modules termed ‘hubs’. This
analysis alleviates several testing problems that are inevi-
table in standard gene centric methods, making WGCNA a
powerful tool in cancer studies [22]. Based on a mean gene
expression value of TPM > 5 across patient samples, 19,913
genes were selected for WGCNA. These genes produced 41
co-expression modules comprising 16,369 genes (3544
genes were filtered because they do not cluster to any
module) (Fig. 3b and Supplementary File 3). For each of the
41 modules, we identified a hub gene (Supplementary File
3). We examined hubs likely to be involved in metastasis by
searching for modules that were enriched for DE genes
(control vs. primary tumour, control vs. metastasis, primary
tumour vs. metastasis). Twenty-six modules were enriched
for DE genes (Fisher’s exact test p ≤ 0.05). Heat maps based
on normalised TPM values of these 26 modules showed
different expression patterns in PBC metastasis to the lung.
We selected the Green module (Fig. 3c and Supplementary
File 3) where E2F transcription factor 1 (E2F1) was the hub
gene because E2F1 mediates TP53-dependent apoptosis.
This pathway is critical for the current study because of the
TP53−/− driver mutation described earlier [23].
All 1045 genes in the Green module were subject to gene
ontology (GO) analysis (Fig. 3d) to show spatial repre-
sentation of enriched GO terms plusmolecular functions
significantly affected (Fig. 3e). Within these analyses, we
observed matrix metallopeptidase 9 (MMP9) as a candidate
pro-metastatic gene. We had also noted MMP9 as a highly
expressed gene in our previous analyses (Figs. 1, 2 and
normalised data on GEO), so we selected MMP9 for further
investigation. The other 25 modules were not explored
further here, but are freely available in Supplementary
File 3.
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MAPK7 is an MMP9 master regulator and drives
lung metastasis in vivo
MMP9 is a prognostic marker for several cancers, with
several studies showing its role in angiogenesis, extra-
cellular matrix and surface receptor cleavage [24–26].
MMP9 inhibitor drugs have had limited success in patient
trials [27]. One explanation for MMP9 drug failure is that
targeting the catalytic component of MMP9 is insufficient
for effect. We asked whether targeting the MMP9 transcript
preventing protein translation may show improved out-
comes, so we opted to test the MMP9 upstream regulator
mitogen-activated protein kinase 7 (MAPK7), that is, our
goal was to target a master regulator to ‘action’ the ‘unac-
tionable’ MMP9. Supporting this experimental strategy was
that MAPK7 also has roles in metastatic cancer [28–33], so
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we would likely ‘hit’ several other genes/pathways as well
as MMP9. We cloned highly metastatic human 143B cells
with stably expressed short hairpin RNA (shRNA) to sup-
press MAPK7 (shMAPK7) (Fig. 4a, b), which had no
impact on proliferation in vitro (Supplementary Fig. 2a). To
monitor growth of the primary tumour plus tumour dis-
semination to the lungs, we used luciferase-tagged cells,
which also had no impact on proliferation in vitro
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(Supplementary Fig. 2b). Control and shMAPK7 luciferase-
tagged cells displayed comparable, constitutive luciferase
activity and bioluminescence signal directly correlated to
tumour size in vivo (Supplementary Fig. 2c). We engrafted
transfected cells into the femur of immunocompromised
mice and tracked metastatic colonisation in the lungs [34].
MAPK7-deficient tumours were grown to the same size as
control tumours before being tested for metastatic potential
and lung clonogenicity, ensuring we compared ‘like for
like’. Metastatic cells harbouring shMAPK7 showed sig-
nificantly reduced MMP9 transcript and MMP9 protein
expression (Fig. 4c, d). shMAPK7 tumour growth was
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markedly slower plus cells showed significantly reduced
ability to colonise the lungs (Fig. 4e). Lung metastases were
undetectable by haematoxylin and eosin (H&E) staining in
mice harbouring shMAPK7 tumours (Fig. 4f). Lung clo-
nogenicity, which can be used to detect micrometastases
undetectable by H&E staining, showed practically no
spread to the lung from shMAPK7 tumours (shMAPK7=
0.092 colonies per mg, controls= 4.43 colonies per mg of
lung, p ≤ 0.001) (Fig. 4g) or any other organ (data not
shown). These data show that MAPK7 is a master regulator
of MMP9 expression, and reduction of this signalling axis
inhibits spread to the lungs.
MAPK7/MMP9 signalling localises to the invasive
margin
Metastasis is independent of tumourigenesis, which is
mostly driven by tumour growth. Metastasis can be defined
by other features, including invasiveness and colonisation,
so we next addressed the MAPK7/MMP9 signalling origin.
We used in vivo fluorescence imaging using an
MMP9 substrate that fluoresces upon proteolytic cleavage
[35]. Fluorescence signal indicative of active MMP9
laterally increased with tumour growth in controls (Fig. 5a,
b). Tumour cells harbouring shMAPK7 showed sig-
nificantly reduced fluorescence signal in both primary
tumour and metastases (Fig. 5a, b). We verified fluores-
cence imaging by analysing MMP9 expression in tumour
lysates plus gross histology. MMP9 signal was mostly
localised to the tumour edge, that is, the invasive margin
(Fig. 5c, arrow lower panel). shMAPK7 tumours displayed
MAPK7 in stromal regions only (Fig. 5c, arrow upper
panel). Tumours lacking functional MAPK7 showed MMP9
protein loss (Fig. 5c, d). These data show that MAPK7/
MMP9 signalling plays a role at the tumour–stroma border.
Blockade of MAPK7/MMP signalling axis suppresses
monocyte infiltration, TAM accumulation,
tumourigenesis and lung metastasis
Previous work in skin and lung cancer shows that MAPK7
promotes pro-tumour inflammation plus ‘M2-like’ polar-
isation of tumour-associated macrophages (TAMs) [29, 36].
Since (i) recent evidence has shown that there is significant
crosstalk between osteosarcoma and the immune system
[14], (ii) TP53−/− triggers WNT-dependent systemic
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Fig. 5 MAPK7/MMP9 signalling localises to the invasive margin.
a Fluorescence imaging to detect active MMP9 in tumours in vivo.
Tumours lacking MAPK7 had no detectable MMP9 activity. Images
are from size-matched control and shMAPK7 tumours. b Quantified
FLI signal in tumours over time. FLI signal indicative of MMP9
activity increases over time in control, but not shMAPK7 tumours.
c IHC analysis of tumour biopsies. shMAPK7 tumours display marked
reduction in MAPK7 expression, but still display MAPK7-positive
cells in the stroma (arrow). MMP9 expression was observed at the
leading edge of control tumours (arrow), but was undetectable in
shMAPK7 tumour biopsies. Scale bar is 100 μM. d qPCR analysis of
ex vivo tumour lysates. shMAPK7 tumours have significantly less
MMP9 mRNA expression. MMP9 mRNA levels were normalised to
PGK1 (p ≤ 0.001). Representative images are used to describe data
collected from 12 mice per group. Data are mean ± SD of three bio-
logical replicates. *p ≤ 0.05, **p ≤ 0.001.
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inflammation that stimulates TAMs to perform breast cancer
metastasis [37], and (iii) our data here in a TP53−/−-driven
cancer that shows MAPK7 regulates MMP9 and is involved
in lung metastasis, we strongly suspected that MAPK7/
MMP9-driven TAMs were mediators of osteosarcoma
metastasis [14, 37]. We performed immunohistochemistry
(IHC) plus cell sorting of immune cell composition in
control and shMAPK7 tumours. Fluorescence-activated cell
sorting (FACS) analysis showed a significant reduction in
CD45+ tumour infiltrates, that is, there were fewer immune
cells present in shMAPK7 tumours (data not shown). To
directly compare immune cell constitution or ‘immune
contexture’ between control and shMAPK7 tumours, we
normalised immune cell numbers to the total number of
CD45+ cells in each sample (Fig. 6a). The immune con-
texture in shMAPK7 tumours was composed of fewer
macrophages, greater numbers of neutrophils plus a greater
number of monocytes (Fig. 6a). We isolated macrophages
from shMAPK7 tumours. These macrophages displayed an
impaired ability to produce MMP9 despite having intact
MAPK7 themselves (Fig. 6b). Non-invasive imaging using
18F DPA-714 to detect translocator protein (TSPO) expres-
sing cells in vivo [38] that are predominantly macrophages
showed a significant decrease (p ≤ 0.01) in macrophage
infiltration in shMAPK7 tumours (Fig. 6c). We next used a
pan macrophage F4/80 marker to show that control primary
tumours contained higher levels of macrophage infiltration
when compared to shMAPK7 tumours (Fig. 6d).
Macrophage-rich regions in control primary tumours co-
localised with MAPK7 expression (Fig. 6e). ‘M2-like’ and
MAPK7-expressing TAMs were almost completely absent
in the lungs of mice with shMAPK7 tumours (Fig. 6f).
These observations were despite the fact that macrophages
and lung tissue have intact MAPK7. Together, these
experiments show that a MAPK7 signal derived from pri-
mary tumour cells regulates TAM polarisation, TAM
expression of MMP9, TAM infiltration and TAM-mediated
metastasis to the lungs.
Discussion
Complex human diseases such as cancer accompany
widespread reprogramming of gene expression. A com-
prehensive understanding of the disease state requires not
only the identification of DE genes, but also understanding
the cellular and physiological responses to dysregulated
expression patterns. Here our analyses allowed us to view
the transcriptomic alterations that underpin PBC metastasis
at whole tumour and single-cell resolution. We have
uncovered several transcripts involved in PBC malignant
progression that were undetected in previous genomic stu-
dies. Some of these genes and regulatory network hubs are
clinically actionable with available drugs. Out of the sig-
nificant amount of data generated here, we interrogated
MMP9 owing to its extremely high expression plus recur-
rent observation in our models. Experimental data on
MMP9 was independently achieved across two separate
laboratories supporting our inference that MMP9 is
involved in PBC spread to the lungs. Our experiments
showed that MAPK7 is an upstream master regulator of
MMP9 and is responsible for driving metastasis. This
observation is consistent with in vitro models and tail vein
injection metastasis models [30, 32, 33]. Here we modelled
lung metastasis with markedly more biological and clinical
significance because we tracked metastatic spread of human
cancer that produced orthotopic tumours.
Tumour cells harbouring shMAPK7 showed impaired
tumour growth compared to controls. No difference in
proliferation was observed between control and shMAPK7
143B cells in vitro (Supplementary Fig. 2d). We hypothe-
sised the delayed growth of shMAPK7 tumours in vivo was
due to shMAPK7 tumours lacking the ability to effectively
crosstalk with the stromal and immune compartments,
which can accelerate tumour growth. We have shown in
other studies that MAPK7 is a fundamental requirement for
a pro-tumour immune contexture [28, 29].
We showed a MAPK7 signal and/or MAPK7 sensitivity
is required for PBC metastatic spread to the lungs. Meta-
static spread to other parts of the body, including other
skeletal sites, was not observed in the timeframe of this
study. To control for the slower growth rate of shMAPK7
tumours versus controls, we tested metastatic spread to the
lung at equivalent tumour sizes in each cohort. The longer
time taken for shMAPK7 tumours to reach equivalent size
to their control counterparts increased the overall tumour
residency time, which we know from several studies posi-
tively correlates with increased metastatic risk. This illus-
trates that the lack of development of lung metastases from
shMAPK7 tumours is even more significant.
Previous work on MAPK7 has shown it to be a driver for
epithelial–mesenchymal transition (EMT) [39]. PBC arises
from and is itself a mesenchymal tissue. EMT is all but
redundant in this context. We focussed our evaluation of
driver mechanisms underpinning our observations on the
immunological effects of MAPK7 loss, as seen in other
cancer models, and the interaction with MMP9 signalling
therein.
Fundamental to several cancers is a specific macrophage
population arising from blood monocytes. TAMs are per-
petually recruited to tumours. In early tumours, TAMs
present an inflammatory and tumoricidal ‘M1-like’ pheno-
type. As tumours progress, TAMs are functionally repro-
grammed by tumour-derived signals to exhibit a trophic,
angiogenic and immune inhibitory ‘M2-like’ phenotype that
contributes to advancing cancer [29]. Here MAPK7
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differentiation and lung metastasis. a FACS analysis of the immune
profiles of control and shMAPK7 tumours. Immune profiles are nor-
malised to the total CD45+ cells (% of parent myeloid cells) in each
sample to enable direct comparison between groups. We show immune
profiles from three representative control and shMAPK7 tumours.
Data are presented as the percentage of parent: myeloid cells. b qPCR
analysis of macrophages isolated from tumours. MMP9 mRNA was
normalised to ACTB. Macrophages from shMAPK7 tumours have
significantly less MMP9 expression suggesting tumour
MAPK7 signalling regulates macrophage MMP9 expression. c Posi-
tron emission tomography (PET) imaging using 18F DPA-714 tracer to
detect intratumoural macrophage expression. Representative end point
PET images are shown (heat map images). Tumours lacking MAPK7
have fewer macrophages than size-matched control tumours, and
unlike control tumours, they do not display an increase in macrophage
influx over the course of tumour growth (graph) (p ≤ 0.001).
d Chromogenic IHC analysis of tumour biopsies. shMAPK7 tumours
display marked reduction in intratumoural macrophages (F4/80).
e Fluorescent IHC analysis of tumour biopsies. shMAPK7 tumours
have significantly fewer macrophages (F4/80). MAPK7 expression co-
localises with macrophages in control tumours and is absent in
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tumour bearing animals. Few ‘M2-like’ TAMs are detected in the
lungs of mice bearing shMAPK7 tumours compared to a strong
infiltration of ‘M2-like’ TAMs in the lungs of animals bearing control
tumours (MR). Lungs from control animals have greater MAPK7
expression when compared to the lungs of animals bearing shMAPK7
tumours. Together this shows a tumour MAPK7 signal controls both
TAM infiltration and MAPK7 activity at the metastatic site (lung).
Scale bars are 100 μM. Representative images are used to describe data
collected from 12 mice per group. Data are mean ± SD of three bio-
logical replicates. *p ≤ 0.05, **p ≤ 0.001.
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silencing strongly minimises TAM infiltration at the tumour
site while increasing the monocyte content. This finding
supports the conclusion that MAPK7 controls TAM
maturation and phenotype, which is also observed in other
cancer types [29]. MAPK7 loss affects macrophage resi-
dency and the lung phenotype of tumour bearing animals
despite MAPK7 loss only occurring in tumour cells.
MAPK7 expression co-localises with TAMs at both the
primary and secondary site. The lungs of mice bearing
tumours lacking MAPK7 have fewer ‘M2-like’ macro-
phages. These observations suggest that a tumour-derived
MAPK7 signal supports the lung microenvironment to be
conducive to metastases by supporting macrophage influx
and by directing their polarisation to a pro-metastatic ‘M2-
like’ phenotype. MAPK7 loss in primary tumours decreases
MAPK7 expression in the lungs, suggesting that MAPK7
regulates a positive feedback loop for its own expression
between the primary and metastatic site. MAPK7 loss in
xenograft tumours reduces MMP9 expression in TAMs that
have intact MAPK7, further supporting our assertion that
MAPK7 signals dictate TAM behaviour and phenotype.
Taken together, this work shows that a tumour-derived
MAPK7 signal dictates macrophage behaviour at the pri-
mary site plus secondary lesion to provide molecular cues
for immune contexture and metastatic spread in PBC.
Owing to the prevalence of TAMs in solid cancer plus
their unique influence on disease progression, macrophage-
targeted interventions have attracted prominent attention in
cancer immunotherapy. Amenable targets to reduce TAM
polarisation and infiltration are few because the signalling
mechanisms underpinning malignant macrophage pheno-
types are largely unknown. Here we have investigated the
role of the MAP protein kinase MAPK7 as a determinant of
macrophage polarity. Our data strongly implicate that
TAMs drive metastasis to the lung using MAPK7/MMP9 in
an autocrine and paracrine fashion [40, 41]. Targeting
MAPK7 affects the downstream expression of several other
genes as well as MMP9 (Supplementary Fig. 2d). Simul-
taneously targeting a broad range of genes will likely be
required for clinically effective outcomes, that is, targeting
MMP9 plus other metastatic contributors, which could be
made possible by targeting MAPK7.
There are currently no effective MAPK7 inhibitors.
Older generation inhibitors had significant off-target effects
that accounted for their observed phenotypes, but were
originally attributed to MAPK7 [42]. The newest generation
of MAPK7 kinase inhibitors have little if any effect on
transcription of cancer-promoting genes [42]. Recent work
shows MAPK7 kinase inhibitors can paradoxically activate
MAPK7 [43]. This recent discovery plus our own previous
work with genetic models of MAPK7 loss show that loss of
all MAPK7 functions, that is, its catalytic function plus non-
catalytic transcriptional function, is required to successfully
target MAPK7 for therapeutic gain [28, 29, 44]. None of the
available inhibitors are able to inhibit all aspects of MAPK7
function, but future drug development should focus on
achieving this objective.
Analytical tools that mine quantitative measurements of
mRNA to identify key regulatory interactions and/or sig-
nalling can provide an effective avenue for identifying
previously unknown molecular mechanisms with critical
functions in health and disease. These computational stra-
tegies must be paired with rigorous experimentation to
functionally validate and characterise the putative physio-
logical outcome. Using this approach, we have established
the role of a MAPK7/MMP9 signalling axis in recruiting
TAMs to PBC tumours to induce lung metastasis. Remov-
ing the MAPK7/MMP9 signalling axis by RNA inter-
ference suppressed tumour burden, metastatic spread and
increased overall survival in animals by inhibition of TAM
infiltration. Our findings provide new insights into the
mechanisms of PBC metastatic progression mediated by
TAMs that may advance the development of immune-based
strategies. Our results also demonstrate the value of
unbiased sequencing strategies, such as whole tumour plus
single0ell RNA0sequencing that do not rely on prior
knowledge of annotated regulatory programs. The approach
here finds that blockade of MAPK7/MMP9 signalling may
overcome current hurdles for targeting pathways that ulti-
mately lead to metastatic lung nodule formation in a
childhood cancer.
Materials and methods
Patient samples
The University of East Anglia Faculty of Medicine and
Health Sciences Research Ethics Committee approved the
collection and study of human samples (Reference: 2015/16
100 HT). We obtained patient material from the Royal
Orthopaedic Hospital, Royal Papworth Hospital and the
UCL Biobank (n= 21). We confirmed high-grade osteo-
blastic osteosarcoma at biopsy and at resection. All indivi-
duals provided written informed consent to donate blood/
tissue to this study. We used publicly available datasets
from the European Nucleotide Archive (https://www.ebi.ac.
uk/ena) and combined with our patient series before pro-
cessing through our bioinformatics pipeline (n= 9).
CTC capture and imaging
We isolated CTCs from 7.5 ml whole blood in EDTA using
the ClearCell FX (Biolidics). Cells were deposited in 10 ml
resuspension buffer, centrifuged at 500 × g for 10 min, the
supernatant was removed, and then 100 μl was transferred
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to a Nunclon plate (Thermo Fisher Scientific). For imaging
live cells, CTCs were cultured in DMEM (Dulbecco’s
modified Eagle’s medium) high glucose (Thermo Fisher
Scientific) containing 10% (v/v) foetal bovine serum (FBS)
(Sigma-Aldrich) and 1% (v/v) penicillin–streptomycin. We
cultured for 5 days and maintained at 37 °C in 5% CO2. For
single-cell RNA-sequencing, we manually picked CTCs
under a microscope using a P10 pipette set to 1 μl and
placed individual cells into 10 μl of lysis buffer. We stained
live CTCs with Hoechst 33342 (Thermo Fisher Scientific), a
cell surface vimentin monoclonal antibody (Abnova) and a
CD45 monoclonal antibody (BD Biosciences). Blue fluor-
escence was excited at 365 nm and emission collected
between 420 and 470 nm. Red fluorescence was excited at
558 nm and emission was collected through a 615 nm LP
filter. Green fluorescence was excited at 400 nm and emis-
sion collected through a 525 nm LP filter. We imaged CTCs
using an Axiovert 200M microscope (Zeiss) with an
Axiocam MRm CCD camera (Zeiss) under the control of
AxioVision.
Library preparation and next-generation
sequencing
We extracted total RNA using the miRNeasy mini kit
(Qiagen) according to the manufacturer’s instructions. We
measured concentration and integrity on the NanoDrop
8000 Spectrophotometer (Thermo Fisher Scientific). RNA
was stored at −80 °C. We used the NEBNext ultra II RNA
library prep kit (New England Biolabs) and SMART-seq v4
ultra low input RNA kit (Takara) to generate libraries. We
performed 150 bp PE sequencing on a HiSeq 2500
(Illumina).
Bioinformatics
We converted fastq files to fasta. We used Trim Galore to
remove adapter sequences and reads <20 nt. Trimmed reads
were aligned to the human genome (v38) using HISAT2
[45]. Transcripts were download from GENCODE (v28)
and Ensembl (v92). Count matrices for transcripts were
created using Kallisto [46]. We determined DE transcripts
using the DESeq2 package in R (v1.2.10) [47]. We selected
DE mRNA according to log2 fold change ≥2, p ≤ 0.05 and
false discovery rate (FDR) <5%.
Alternative splicing analysis
We examined alternative splicing events from aligned BAM
files using rMATS [48]. rMATS quantified exon/intron by
inclusion junction counts and skipped exon/intron by
skipping junction counts. The difference in inclusion level
for each candidate splicing event was calculated using reads
that map to the body of exons as well as splice junctions
from control and tumour samples. Differentially spliced
events were required to have an absolute difference in
inclusion level >10% plus an FDR < 10%. We used
rMATS2Sashimiplot and Sashimi plot for quantitative
visualisation [49].
Gene expression analysis
To validate sequencing datasets, we performed gene
expression analysis using a modified PanCancer Pathways
Panel (NanoString Technologies) comprising 800 genes,
including 12 housekeeping genes (Supplementary File 4).
We used an nCounter Digital Analyser (NanoString Tech-
nologies) to count the digital barcodes representing the
number of transcripts. Raw counts were automatically
normalised by the total counts of all the tested samples and
housekeeping genes in order to compensate for variations
introduced by experimental procedures. We averaged
counts between replicates using the nSolver analysis soft-
ware and log2 transformation. We used the most stringent
method (mean ± 2 SD) to accept detected transcripts.
Gene set enrichment in CTCs
We ranked sequencing reads confirmed by nanostring into a
numerical expression list. We built a network of functional
interactions between the genes using STRING (v11). The
line colour connecting genes indicates the known and pre-
dicted interactions. Blue lines represent data from curated
databases. Pink lines represent data from experiments.
Green lines represent gene neighbourhoods. Black lines
represent co-expressed genes.
Weighted gene co-expression network analysis
WGCNA was used to generate unsigned co-expression
networks in controls, primary tumours and metastatic
tumours [21]. Transcripts with normalised counts (TPM) >
5 were used for the co-expression analysis. WGCNA
clusters genes into network modules using topological
overlap measure (TOM). TOM is a robust measure of net-
work interconnectedness and measures the connection
strength between two adjacent transcripts and all other
transcripts in a network. Hierarchical clustering was used to
group transcripts based on dissimilarity of transcript con-
nectivity, which is defined as 1-TOM. We used the
cutreeDynamic function to produce co-expression clusters.
The minimum size of modules was 20 transcripts and were
randomly colour labelled. An adjacency matrix was built by
applying a power function (β) on the Pearson correlation
matrix. The β was optimised to be 18 for balancing the
scale-free property of the co-expression network and the
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sparsity of connections between transcripts. Intramodular
connectivity of transcripts was used to identify hubs in the
modules.
Cell culture
We obtained 143B (osteosarcoma) cells from ATCC. We
authenticated cells by STR profiling. We cultured cells in
DMEM (Thermo Fisher Scientific) containing 10% (v/v)
FBS (Sigma-Aldrich) and 1% (v/v) penicillin–streptomycin.
We refreshed culture media every other day and maintained
at 37 °C in a atmosphere of 5% CO2. Cells were regularly
monitored for Mycoplasma infection by PCR. Similar pas-
sage number was used in biological replicates in vitro and
for implants in vivo.
Immunoblotting
We extracted proteins in radioimmunoprecipitation assay
buffer containing protease and phosphatase inhibitors. We
resolved extracts (30 μg) by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and electrophoretically
transferred to an Immun-Blot® PVDF membrane (Bio-Rad).
Membranes were saturated in 3% non-fat dry milk or 3%
bovine serum albumin (BSA) and probed overnight at 4 °C
with antibodies (1:1000 dilution unless otherwise indicated) to
MAPK7 (Cell Signalling, #3372), MMP9 (Abcam,
#Ab38898) and ACTB (Sigma, #A5316). We detected
immunocomplexes by enhanced chemiluminescence with
immunoglobulin G (IgG)-coupled to horseradish peroxidase as
the secondary anti-rabbit and anti-mouse antibodies (Abcam).
Quantitative polymerase chain reaction
Total RNA was isolated from cells using TRIzol and the
miRNeasy mini kit (Qiagen). We carried out com-
plementary DNA synthesis as previously described [28].
We performed quantitative polymerase chain reaction using
the SYBR green I core kit (Eurogentec). Human MMP9,
5′-GTACTCGACCTGTACCAGCG-3′, 5′-AGAAGCCCCA
CTTCTTGTCG-3′; mouse Mmp9, 5′-GCCGACTTTTGTGG
TCTTCC-3′, 5′-CTTCTCTCCCATCATCTGGGC-3′; human
PGK1, 5′-GAAGATTACCTTGCCTGTTGAC-3, 5′-GCTCT
CAGTACCACAGTCCA-3′. PCR products were detected in
the ABI PRISM® 7700 sequence detection system (Thermo
Fisher Scientific). We analysed results using the 2−ΔΔG
method. Gene expression was normalised to PGK1 or ACTB.
Enzyme-linked immunosorbent assay
We performed MMP9 enzyme-linked immunosorbent assay
(ELISA) using several kits (R&D Systems) according to the
manufacturer’s instructions. Plates were pre-coated with
MMP9 antibody. Briefly, fresh media were collected from
equal numbers of cells and centrifuged to remove debris.
We centrifuged supernatants in Amicon tubes (Millipore).
We incubated plates with samples plus serial dilutions of
provided ELISA standards. Plates were washed and
incubated with a horse radish peroxidase (HRP)-con-
jugated secondary antibody, followed by a further wash
plus incubation with a colorimetric HRP-sensitive sub-
strate. We measured absorbance of the samples at 450 and
540 nM using a UQuant plate reader (BioTek). Absor-
bance at 540 nM was deducted from that at 450 nM to
correct for background signal. We generated standard
curves from the serial diluted standards and concentra-
tions of MMP9 in the samples extrapolated from the
standard curve.
Mice
The University of Manchester Animal Welfare and Ethics
Committee approved animal experiments. Experiments
were performed under licence in accordance with UK Home
Office guidelines and under the Animals (Scientific Proce-
dures) Act 1986. Eight to twelve-week-old CD1-Foxn1nu
female mice were implanted with 0.02 ml of a 6 × 107/ml
suspension containing either control or shMAPK7 143B
cells into the left femur. Mice were housed in a pathogen-
free facility. Mice were killed using Schedule 1 procedures.
A small region of fresh lung was tied off and excised for
clonogenic analysis. We inflated remaining lungs with
formalin. We removed tumours, bisected and half fixed in
10% formalin, quarter digested for FACS analysis and a
quarter frozen in liquid nitrogen for immunoblot or RNA
analysis. For in vivo analysis using similar animal models,
it has been shown that to detect >30% reduction in primary
tumour growth, experiments require five animals per group.
To detect >30% change in metastases with 0.8 power and at
p ≤ 0.05 statistical significance, experiments require eight
animals per group. For imaging to detect >30% changes
with 0.8 power and at p ≤ 0.05 statistical significance,
experiments require ten animals. For ex vivo analyses,
animal numbers required to assess the functional role of
MAPK7 in tumour inflammation and metastases was pre-
viously predicted by power analysis with a minimum of
three tumours taken from three biological replicates for all
analytical techniques [28]. Animal experiments were pow-
ered based on the experimental analysis that required the
largest mouse number (imaging). To accommodate a
potential implant failure rate ~10%, 15 mice per group were
used (n= 15 control, n= 15 shMAPK7). These animals
were divided into three independent experiments (n= 5
control, n= 5 shMAPK7). These numbers provided the
three biological replicates needed to power ex vivo analysis.
Exclusion criteria were those animals that did not develop
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tumours. No randomisation or blinding was used when
allocating animals to experimental groups.
Plasmids
We used pLenti CMV Puro LUC (w168-1) (Addgene) [50].
We used a SMARTvector (Dharmacon) plasmid for
shMAPK7. We used third-generation pMD2_VSVg plus
packaging plasmids pRSV-Rev (Addgene) and pMDLg/
pRRE (Addgene) for luciferase lentiviral transduction. We
used second-generation pMD2G (VSV-G envelope) and
p8.91 (HIV gag/pol) for shRNA plasmids.
Bacterial transformation
Transformation was carried out according to the manu-
facturer’s instructions using MAX Efficiency Stbl2™-
competent cells (Invitrogen). Briefly, 100 μl of Stbl2 cells
were thawed on wet ice and then aliquoted into cold
polypropylene tubes. One microlitre of solubilised plasmid
DNA was added to competent cells and incubated on ice for
30 min. Cells were heat shocked in a water bath at 42 °C for
25 s. Cells were placed on ice for 2 min and then 0.9 ml of
ambient temperature SOC medium (2% tryptone, 0.5%
yeast extract, 8.6 mM NaCl, 20 mM KCl and 20 mM glu-
cose) was added. Ligation reactions were shaken (60 min,
225 r.p.m., 30 °C) and then diluted 1:10 with the SOC
medium. One hundred microlitres was spread onto pre-
warmed LB agar plates with pre-added ampicillin (100 μg/
ml). Agar plates were incubated overnight at 30 °C and then
the colonies were picked and used to produce starter
cultures.
Plasmid starter cultures
Plasmid starter cultures were taken from plasmid glycerol
stocks stored at −80 °C. Using a sterile pipette tip, a small
amount of glycerol stock was scraped into 50 ml centrifuge
tubes containing 5 ml LB broth plus ampicillin (100 μg/ml).
The CMV Puro LUC plasmid was picked from single
colonies grown up from bacterial transformations. Starter
cultures were grown at 30 °C for 8 h at 225 r.p.m. Five
millilitre starter cultures were transferred to 500 ml LB
broth in conical flasks containing 100 μg/ml ampicillin and
incubated overnight at 30 °C at 225 r.p.m. to obtain large
amounts of plasmid DNA.
DNA purification
Concentrated plasmid DNA was prepared using the Endo-
free plasmid mega kit (Qiagen) according to the manu-
facturer’s protocol. Briefly, bacterial cells were lysed and
then cleared via a filter. Endotoxins were removed from the
cleared lysate that was then loaded onto a binding column.
RNA, protein and other impurities were removed by
washing. Plasmid DNA was eluted in a high salt buffer.
Plasmid DNA was concentrated and desalted by iso-
propanol precipitation and collected by centrifugation then
resuspended in TE buffer.
High titre lentiviral vectors
To generate high titre lentivirus, we plated 1.5 × 106 HEK
293T cells on 150 mm dishes (Corning) containing 16.5 ml
antibiotic-free complete media and incubated overnight to
adhere. For luciferase expression, cells were transfected the
following day with the expression plasmids CMV Puro
LUC, pMD2_VSVg, pRSV-Rev and pMDLg/pRRE in a
2:1:2:1 ratio. For MAPK7 knockdown, cells were trans-
fected the following day with expression plasmids pMD2G
and p8.91 in a 3:1 ratio. Plasmids were diluted in 150 mM
NaCl (3 ml per plasmid) in a 50 ml Falcon (Corning). Three
millilitres of polyethylenimine (PEI)/NaCl solution (1:12
ratio of 15 mM PEI:150 mM NaCl) was added dropwise to
each plasmid dilution and incubated for 10 min at room
temperature and then the plasmid/PEI solution was evenly
distributed dropwise at 2 ml per plate. Twelve hours post
transfection, media were aspirated and replaced. Forty eight
hours post transfection, viral supernatant was aspirated and
collected in 50 ml Falcon tubes, while fresh complete media
were added to the plates. Falcons were centrifuged (5 min,
112 × g, 4 °C) to remove cell debris and filtered through a
pre-wet 0.45 μm cellulose acetate filter (Corning) using a
vacuum pump. The supernatant was then transferred into
50 ml Falcon tubes able to withstand high-speed cen-
trifugation (Alpha Laboratories). Falcons were then cen-
trifuged (2.5 h, 13,500 × g, 4 °C) to obtain viral pellets. The
supernatant was aspirated and pellets resuspended in 100 μl
formulation buffer (phosphate-buffered saline (PBS), 1 mg/
ml human serum albumin, 5 μg/ml protamine sulphate),
aliquoted and stored at −80 °C. A second harvest was
conducted using the same protocol 72 h post transfection.
Viral titre determination
We seeded 143B cells at 1 × 105 cells per well in 12-well
plates and left to adhere overnight. The following day, cells
in one well were counted and then the remaining wells were
infected with serial dilutions of lentiviral vector (10−3–10−5
per 1 ml medium). Media were changed after ~12 h, and
then after 48-h incubation (37 °C, 5% CO2), cells were
detached and transferred to microcentrifuge tubes. For
luciferase titre determination, cell pellets were resuspended
in 100 µl 4% paraformaldehyde and incubated at room
temperature for 20 min. Fixed cells were resuspended in
permeabilisation buffer (PBS, 0.5% BSA, 0.1% Triton X)
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for 10 min and then stained 1:200 for luciferase expression
with anti-firefly luciferase antibody (Abcam) in FACS
buffer (PBS, 0.5% BSA) for 30 min at room temperature.
After primary staining, cells were stained 1:1000 with
Alexa Fluor® 488-conjugated goat anti-mouse IgG sec-
ondary antibody in FACS buffer. TOPRO-3 was diluted
1:1000 in FACS buffer and 3 µl was added to each sample
to determine cell viability. shRNA-infected cells were sor-
ted live by green fluorescent protein expression. All samples
were sorted on the FACS Canto II flow cytometer and
analysed using the FACSDiva software (BD Biosciences).
Lung clonogenic assay
Fresh lung pieces were digested using Liberase reagent 1 U/
ml (Promega) supplemented with DNase 100 U/ml (Sigma)
for 30 min at 37 °C with mild agitation. We passed cell
digests through a cell strainer and the resultant single-cell
suspension was centrifuged for 2 min at 1400 r.p.m. We
plated cells at serial dilutions in six-well plates and grew in
conditions favouring tumour cell growth, that is, 2 weeks in
RPMI media containing 10% FBS and 1% glutamine.
Colonies formed from tumour cells resident in the lung
were fixed with 70% ethanol and stained with 1% methy-
lene blue (Sigma). We blind counted positive colonies and
were expressed as the number of colonies per milligram of
lung tissue from which they originated.
Bioluminescence and fluorescence imaging
For bioluminescence, mice received an intraperitoneal
injection (150 mg/kg) of VivoGlo™ Luciferin (Promega)
5 min before imaging. For fluorescence, mice received an
intravenous injection (2 nmol per mouse) of MMPSense™
750 FAST (PerkinElmer) 18 h before imaging. Signals plus
grey-scale photographic images were acquired using a
Photon Imager™ (Biospace) and M3 Vision (Biospace).
We maintained animals under general anaesthesia with
1–2% isoflurane, plus warming and monitoring, during
image acquisition. We carried out signal quantification
(photons/s/cm2/sr) using M3 Vision (Biospace).
IHC (fluorescent and chromogenic)
We immunostained 5-μm-thick tissue sections with anti-
bodies to MAPK7 (Cell Signalling, #3372, 1:200 dilution),
F4/80 (Abcam, #Ab6640, 1:100 dilution), MMP9 (Abcam,
#Ab38898, 1:200 dilution) and mannose receptor (MR)
(1:1000 custom made). The reaction was revealed using
either Vectastain ABC system (Vector Labs), followed by
DAB (Vector Labs) and counterstained with haematoxylin
(chromogenic IHC) or by fluorescence-conjugated Alexa
Fluor secondary antibodies (Abcam, #A21054, #Ab150080,
1:1000) counterstained via DAPI (4′,6-diamidino-2-pheny-
lindole) mounting medium (Abcam) (fluorescent IHC).
Fluorescence-activated cell sorting
We generated cell suspensions from fresh tumour biopsies
using Liberase reagent 1 U/ml (Promega) supplemented
with DNase 100 U/ml (Sigma). Mononuclear single-cell
suspensions were analysed by FACS. Briefly, cells were
pelleted, washed twice and suspended in FACS solution
(PBS containing 10% FBS). Cells were incubated for
30 min at 4 °C before being stained with the following
antibody fluorophore conjugates: F4/80-P610 (Miltenyi,
#130-107-709), CD11b-BUV661 (BD, #565080), CD45-
A700 (BD, #565478), CD3-PeCy7 (BD, #560591), CD4-
PCP Cy5.5 (BD, #561115), CD25-421 (BD, #564571),
CD127-PE (BD, #562419), Ly6C-APC cy7 (BD, #128026)
and Ly6G-AF-488 cy5.5 (BioLegend, #127625). Compen-
sation bead analysis was used to define fluorescence chan-
nel parameters. We assessed cell viability by DAPI
(Molecular Probes) to discriminate dead from live cells. We
performed flow cytometry with a FACScan (BD) and ana-
lysed using the FlowJo software. Data were generated as %
of parent: myeloid cells. FACS gating strategy is shown in
Supplementary Fig. 3.
Positron emission tomography (PET)
Mice underwent dynamic baseline scanning when tumour
size had reached ~200 mm3. We anaesthetised mice with
1–2% isoflurane. We catheterised the tail vein and placed
mice in animal beds, that is, Minerve small animal envir-
onment system (Bioscan). We transferred beds to a pre-
clinical PET/computed tomography scanner (Siemens). At
the start of the acquisition, mice were injected with
~10MBq of 18F DPA-714. We collected list mode data for
1 h. We maintained anaesthesia during image acquisition
via a nose cone with respiration and temperature monitored
throughout. Mice recovered in a warmed chamber after
imaging. We re-scanned mice at 14 and 28 days after the
start of treatment.
Image reconstruction and data analysis
Before image reconstruction, the list mode data were his-
togrammed with a span of three and maximum ring dif-
ferences of 79 into 3D sinograms with 19 time frames (5 ×
60 s, 5 × 120 s, 5 × 300 s, 3 × 600 s). We reconstructed
images using the 3DOSEM and MAP algorithm (four
OSEM3D iterations plus no MAP iterations with a
requested resolution of 1.5 mm). We manually drew regions
of interest (ROIs) over tumour, bone and contralateral bone
as a reference using Inveon Research Workplace (Siemens).
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We performed further normalisation using the injected dose
from the dose calibrator and mice weight to give a stan-
dardised uptake value (SUV). We calculated SUV mean as
the average over all voxels within the ROI. We calculated
normalised uptake value by dividing the SUV mean from
the tumour and the tumour bearing bone from the con-
tralateral bone. We performed normalisations in case the
treatment caused systemic effects that would modify tracer
uptake in healthy tissue.
Statistical analysis
We evaluated variability between sequencing libraries using
scatter plots, size-split box plots of the replicate-to-replicate
differential expression, intersection and Jaccard similarity
analysis [51]. Empirical differential expression was con-
firmed by parametric (t) and non-parametric
(Mann–Whitney U, Wilcoxon’s signed-rank) tests. Differ-
ences in PET signal over time and sample tested were
confirmed with two-way analysis of variance. For all sta-
tistical tests, we considered p ≤ 0.05 as statistically sig-
nificant. All data presented in Figs. 1–3 passed log2 fold
change ≥2, p ≤ 0.05 and FDR ≤ 5% parameters.
Data availability
All data supporting the findings of this study are available
within the article and Supplementary files or from the cor-
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